Image

Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults

Recruiting
5 - 45 years of age
Both
Phase N/A

Powered by AI

Overview

The investigators will utilize a systematic approach for the diagnostic evaluation of patients to identify characteristics which may distinguish between Primary Immunodeficiency (PID) disorders versus Primary Ciliary Dyskinesia (PCD).

Description

This protocol utilizes a cross-sectional study design. Over a 5-year period, the investigators will enroll patients who have clinical and lab features characteristic of a PID disorder or PCD, but do not have a confirmed genetic diagnosis. Innovative, standardized methods (SOPs) will be utilized, including ciliary ultrastructural analyses by transmission electron microscopy (TEM), as pertinent. Measures of nasal nitric oxide (nNO) will be performed in all subjects to allow comparisons of nNO values in PID vs. PCD. Patients with high likelihood of a PID disorder or a high likelihood of PCD will initially undergo research genetic testing on a commercial approved panel for PID disorders or a panel of at least 37 PCD genes. All subjects who do not have a genetic diagnosis from the test panels will undergo whole exome sequencing (WES) to search for novel genetic etiologies for PID or PCD.

Eligibility

Pediatric subjects (aged 5-17 years): Inclusion criteria include the major criterion

        (bronchiectasis in > 1 lobe on current or chest CT in previous 24 months, if available for
        review), plus one minor criterion, or two minor criteria, if bronchiectasis is not present,
        (including at least 1 "lung" minor criteria).
        Adult subjects (aged 18-45 years): Inclusion criteria include the major criteria
        (bronchiectasis in > 1 lobe on current or chest CT in previous 36 months, if available for
        review), plus one minor criterion, or three minor criteria, if bronchiectasis is not
        present, (including at least 1 "lung" minor criteria).
        Inclusion Criteria:
        General Criteria
          -  Age 5-45 years
          -  Male and Female Subjects
          -  All races and ethnicities
        Major Clinical Criteria
        - Bronchiectasis in > 1 lobe
        Minor Clinical Criteria, Lung
          -  Neonatal respiratory distress (in term neonates with O2 requirement)
          -  Chronic wet cough (year-round for at least 12 months)
          -  Recurrent episodes of bacterial bronchitis
          -  Recurrent pneumonia (confirmed on chest x-ray)
          -  Respiratory non-tuberculous mycobacteria (NTM) (documented respiratory NTM culture)
        Minor Clinical Criteria, Other
          -  Chronic nasal congestion
          -  Recurrent/chronic paranasal sinusitis
          -  Ongoing middle-ear disease and/or tympanostomy tube placement at age ≥ 4 years
          -  Organ laterality defect
          -  Low nasal nitric oxide (< 77 nL/min) (by plateau measurement)
          -  Confirmed family history of PID or PCD
        Exclusion Criteria:
          -  Anyone who has a confirmed genetic diagnosis of PCD or PID
          -  Cystic Fibrosis
          -  Alpha-antitrypsin deficiency in adults (18 years and older)
          -  Congenital upper or lower airway anomalies
          -  Post-lung or heart transplant, or other conditions requiring immunosuppression therapy
          -  Other confounding features, such as lung disease due to prematurity (born < 28 weeks
             gestation) or HIV
          -  Neurological compromise and evidence of recurrent aspiration
          -  Conditions known to be commonly associated with bronchiectasis, such as prior
             mycobacterium tuberculosis
          -  Have not had standard clinical evaluation to address other potential causes of chronic
             oto-sino- pulmonary disease, particularly cystic fibrosis, aspiration or airway
             anatomic abnormalities.

Study details

Primary Ciliary Dyskinesia, Primary Immune Deficiency, Kartagener Syndrome

NCT04702243

University of North Carolina, Chapel Hill

15 May 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.